Parkinson’s disease (PD) is one of the most common progressive degenerative diseases, and its diagnosis is challenging on clinical grounds. Clinically, effective and quantifiable biomarkers to detect PD are urgently needed. In our study, we analyzed data from two centers, the primary set was used to train the model, and the independent external validation set was used to validate our model. We applied amplitude of low-frequency fluctuation (ALFF)-based radiomics method to extract radiomics features (including first- and high-order features). Subsequently, t-test and least absolute shrinkage and selection operator (LASSO) were harnessed for feature selection and data dimensionality reduction, and grid search method and nested 10-fold cross-validation were applied to determine the optimal hyper-parameter λ of LASSO and evaluate the performance of the model, in which a support vector machine was used to construct the classification model to classify patients with PD and healthy controls (HCs). We found that our model achieved good performance [accuracy = 81.45% and area under the curve (AUC) = 0.850] in the primary set and good generalization in the external validation set (accuracy = 67.44% and AUC = 0.667). Most of the discriminative features were high-order radiomics features, and the identified brain regions were mainly located in the sensorimotor network and lateral parietal cortex. Our study indicated that our proposed method can effectively classify patients with PD and HCs, ALFF-based radiomics features that might be potential biomarkers of PD, and provided further support for the pathological mechanism of PD, that is, PD may be related to abnormal brain activity in the sensorimotor network and lateral parietal cortex.

Objective: The present study explored whether levetiracetam (LEV) could protect against experimental brain ischemia and enhance angiogenesis in rats, and investigated the potential mechanisms in vivo and in vitro.Methods: The middle cerebral artery was occluded for 60 min to induce middle cerebral artery occlusion (MCAO). The Morris water maze was used to measure cognitive ability. The rotation test was used to assess locomotor function. T2-weighted MRI was used to assess infarct volume. The neuronal cells in the cortex area were stained with cresyl purple. The anti-inflammatory effects of LEV on microglia were observed by immunohistochemistry. Enzyme-linked immunosorbent assays (ELISA) were used to measure the production of pro-inflammatory cytokines. Western blotting was used to detect the levels of heat shock protein 70 (HSP70), vascular endothelial growth factor (VEGF), and hypoxia-inducible factor-1α (HIF-1α) in extracts from the ischemic cortex. Flow cytometry was used to observe the effect of LEV on neuronal cell apoptosis.Results: LEV treatment significantly increased the density of the surviving neurons in the cerebral cortex and reduced the infarct size (17.8 ± 3.3% vs. 12.9 ± 1.4%, p < 0.01) after MCAO. Concurrently, the time required to reach the platform for LEV-treated rats was shorter than that in the saline group on day 11 after MCAO (p < 0.01). LEV treatment prolonged the rotarod retention time on day 14 after MCAO (84.5 ± 6.7 s vs. 59.1 ± 6.2 s on day 14 compared with the saline-treated groups, p < 0.01). It also suppressed the activation of microglia and inhibited TNF-α and Il-1β in the ischemic brain (135.6 ± 5.2 pg/ml vs. 255.3 ± 12.5 pg/ml, 18.5 ± 1.3 pg/ml vs. 38.9 ± 2.3 pg/ml on day 14 compared with the saline-treated groups, p < 0.01). LEV treatment resulted in a significant increase in HIF-1α, VEGF, and HSP70 levels in extracts from the ischemic cerebral cortex. At the same time, LEV reduced neuronal cell cytotoxicity and apoptosis induced by an ischemic stroke (p < 0.01).Conclusion: LEV treatment promoted angiogenesis and functional recovery after cerebral ischemia in rats. These effects seem to be mediated through anti-inflammatory and antiapoptotic activities, as well as inducing the expression of HSP70, VEGF, and HIF-1α.

No abstract

Background: The association of repeated administration of gadolinium-based contrast agents (GBCAs) with the gadolinium (Gd) retention in the brains of mother and fetus remains unclear. Purpose: To investigate the effects of pregnancy and repeated administration of GBCAs on Gd retention in the brains of mother and pup mice. Study type: Cross-sectional cohort toxicity study. Animal Model: From gestational days 16-19, pregnant (n = 48) BALB/c mice. Field Strength: A 9.4 T and fast spin echo sequence. Assessment: Half of the mother mice (n = 24) were killed at postnatal day 1 (P1) for inductively coupled plasma mass spectrometry (ICP-MS) and transmission electron microscopy (TEM). Besides the ICP-MS and TEM, four pups were randomly selected from each mother and killed at P1 for ultraperformance liquid chromatography mass spectrometry (UPLC-MS) and Nissl staining. Statistical Tests: One-way analysis of variance and unpaired t-test. Results: In the group of gadodiamide, retention of Gd in the brains of pregnant mice was significantly lower than that of nonpregnant mice in the area of the deep cerebellar nuclei (DCN) (10.35 AE 2.16 nmol/g vs. 18.74 AE 3.65 nmol/g). Retention of Gd in the DCN of pups whose mothers were administered gadoterate meglumine was significantly lower than that of pups whose mothers were administered gadodiamide (0.21 AE 0.09 nmol/g vs. 6.15 AE 3.21 nmol/g) at P1. In mice treated with gadodiamide, most of the retained Gd in the brain tissue was insoluble (19.5% AE 9.5% of the recovered amount corresponded to the intact complex in the DCN). Data Conclusion: In different brain areas of the mother and pup mice, the retention of Gd after gadoterate meglumine administration was lower than that of gadodiamide and gadopentetate dimeglumine administration, and almost all the detected Gd in pups' brains was intact soluble GBCAs.

No abstract